-1.74%
-10.33%
-24.70%
-27.60%
-35.98%
-49.19%
-37.68%
AI Spotlight on BMK
Company Description
Benchmark Holdings plc, together with its subsidiaries, provides technical services, products, and specialist knowledge that supports the development of food and farming industries in the United Kingdom, Norway, the Faroe Islands, Ecuador, India, Greece, Singapore, Chile, Turkey, rest of the Europe, and internationally.The company operates through Genetics, Advanced Nutrition, and Health segments.The Genetics segment offers salmon breeding technologies and production facilities to the harnesses industry to provide various genetic merit ova.
The Advanced Nutrition segment manufactures and provides nutrition and health products to the aquaculture industry.The Health segment provides health products to the aquaculture market.Benchmark Holdings plc was founded in 2000 and is based in Sheffield, the United Kingdom.
Market Data
| Last Price | 28.2 |
| Change Percentage | -1.74% |
| Open | 28 |
| Previous Close | 28.7 |
| Market Cap ( Millions) | 209 |
| Volume | 10536 |
| Year High | 48 |
| Year Low | 26 |
| M A 50 | 32.59 |
| M A 200 | 38.73 |
Financial Ratios
| FCF Yield | -2.94% |
| Dividend Yield | 0.00% |
| ROE | -16.05% |
| Debt / Equity | 33.02% |
| Net Debt / EBIDTA | 464.15% |
| Price To Book | 0.96 |
| Price Earnings Ratio | -5.28 |
| Price To FCF | -34.02 |
| Price To sales | 2.31 |
| EV / EBITDA | 24.45 |
News
- Dec -25 - Benchmark Holdings Full Year 2024 Earnings: Misses Expectations
- Dec -13 - Benchmark Holdings PLC (BHCCF) (Q4 2024) Earnings Call Highlights: Strategic Moves and ...
- Dec -13 - Benchmark Holdings PLC (BHCCF) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial ...
- Nov -12 - UK Stocks Trading Below Estimated Fair Value In November 2024
- Nov -06 - Is Benchmark Holdings plc (LON:BMK) Trading At A 44% Discount?
- Oct -14 - 3 UK Stocks Including Benchmark Holdings That Might Be Trading Below Estimated Value
- Sep -11 - Benchmark Holdings And 2 Other UK Stocks That May Be Undervalued
- Aug -24 - Benchmark Holdings Third Quarter 2024 Earnings: Misses Expectations
- Apr -20 - Rightmove (LON:RMV) shareholders have endured a 14% loss from investing in the stock three years ago
- Feb -02 - Benchmark Holdings Insider Ups Holding By 18% During Year
- Oct -29 - Shareholders in APG|SGA (VTX:APGN) are in the red if they invested five years ago
- Jul -12 - Benchmark Holdings (LON:BMK) shareholders have endured a 29% loss from investing in the stock five years ago
- May -07 - Benchmark Holdings plc (LON:BMK) Shares Could Be 49% Below Their Intrinsic Value Estimate
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Advanced Nutrition
Expected Growth : 12 %
What the company do ?
Advanced Nutrition from Benchmark Holdings plc provides sustainable and innovative solutions for the aquaculture, agriculture, and pet care industries, enhancing animal health and well-being.
Why we expect these perspectives ?
Advanced Nutrition from Benchmark Holdings plc's 12% growth is driven by increasing demand for sustainable aquaculture, rising adoption of precision farming, and growing consumer preference for healthy and sustainable seafood. Additionally, expansion into new markets, innovative product offerings, and strategic partnerships contribute to the segment's growth.
Segment n°2 -> Genetics
Expected Growth : 11 %
What the company do ?
Genetics from Benchmark Holdings plc refers to the application of genetic science to improve aquaculture and agriculture, enhancing animal health and productivity.
Why we expect these perspectives ?
Genetics segment of Benchmark Holdings plc is driven by increasing demand for sustainable aquaculture, growing adoption of genetic technology in agriculture, and rising need for disease resistance in livestock. Additionally, advancements in genomics and gene editing technologies, such as CRISPR, are fueling growth. These factors contribute to the segment's 11% growth rate.
Segment n°3 -> Health
Expected Growth : 14 %
What the company do ?
Benchmark Holdings plc's Health segment provides animal health products and services, including veterinary pharmaceuticals, vaccines, and diagnostic tools for farmers and veterinarians.
Why we expect these perspectives ?
Benchmark Holdings plc's 14% growth in Health segment is driven by increasing demand for animal health products, expansion into new markets, and strategic acquisitions. Additionally, advancements in genetics and biotechnology, coupled with growing concerns over animal welfare and disease prevention, contribute to the segment's growth.
Segment n°4 -> Intersegment
Expected Growth : 10 %
What the company do ?
Intersegment from Benchmark Holdings plc refers to the elimination of intercompany transactions and balances between subsidiaries, providing a consolidated view of the company's financial performance.
Why we expect these perspectives ?
Benchmark Holdings plc's 10% intersegment growth is driven by increasing demand for sustainable aquaculture, strategic acquisitions, and expansion into new markets. Additionally, investments in genetics and advanced nutrition have improved yields and reduced costs, further boosting growth.
Segment n°5 -> Corporate
Expected Growth : 9 %
What the company do ?
Benchmark Holdings plc's Corporate segment provides sustainable aquaculture and fisheries solutions, offering genetics, advanced nutrition, and health products to the aquaculture industry.
Why we expect these perspectives ?
Benchmark Holdings plc's 9% corporate growth is driven by strategic acquisitions, expansion into new markets, and increased demand for its animal health and aquaculture products. Cost savings from operational efficiencies, investment in R&D, and a strong balance sheet also contribute to its growth momentum.
Segment n°6 -> Discontinued Operations
Expected Growth : 8 %
What the company do ?
Discontinued Operations from Benchmark Holdings plc refers to the financial results of businesses or product lines that are being sold, shut down, or otherwise exited, and are reported separately from continuing operations.
Why we expect these perspectives ?
Benchmark Holdings plc's 8% growth in Discontinued Operations is driven by strategic divestments, improved operational efficiency, and a favorable business environment. The company's focus on core business segments and effective cost management have contributed to this growth. Additionally, the divestment of non-core assets has enabled the company to allocate resources more effectively, leading to increased profitability.
Benchmark Holdings Plc Products
| Product Range | What is it ? |
|---|---|
| Advanced Nutrition | Benchmark's Advanced Nutrition segment provides specialized nutrition products and technical services to the aquaculture industry, helping to improve the health and growth of farmed fish and shrimp. |
| Genetics | Benchmark's Genetics segment provides genetic breeding programs and genetic testing services to the aquaculture industry, helping to improve the growth rates, disease resistance, and sustainability of farmed fish and shrimp. |
| Health | Benchmark's Health segment provides veterinary health products and services to the aquaculture industry, helping to prevent and treat diseases in farmed fish and shrimp. |
| Advanced Animal Diagnostics | Benchmark's Advanced Animal Diagnostics segment provides diagnostic testing services to the animal health industry, helping to detect and monitor diseases in animals. |
Benchmark Holdings plc's Porter Forces
Threat Of Substitutes
The threat of substitutes for Benchmark Holdings plc is moderate, as there are some alternative products and services available in the market, but they are not highly attractive to customers.
Bargaining Power Of Customers
The bargaining power of customers for Benchmark Holdings plc is low, as customers have limited options and the company has a strong brand presence.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Benchmark Holdings plc is moderate, as the company relies on a few key suppliers, but has some flexibility in its supply chain.
Threat Of New Entrants
The threat of new entrants for Benchmark Holdings plc is high, as the industry has low barriers to entry and new companies can easily enter the market.
Intensity Of Rivalry
The intensity of rivalry for Benchmark Holdings plc is high, as the industry is highly competitive and companies are constantly competing for market share.
Strength
Weaknesses
Opportunities
Threats
Capital Structure
| Value | |
|---|---|
| Debt Weight | 26.96% |
| Debt Cost | 7.62% |
| Equity Weight | 73.04% |
| Equity Cost | 7.62% |
| WACC | 7.62% |
| Leverage | 36.90% |
Benchmark Holdings plc : Quality Control
Benchmark Holdings plc passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| PHN.MI | Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The … |
| INCR | InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Israel and internationally. It offers dried cannabis inflorescences and cannabis … |
| PROB.ST | Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune … |
| APH.L | Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and … |
| KMDA | Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Pharmanutra
A-Score
1-Year Total Return ->
🥈
Alliance Pharma
A-Score
1-Year Total Return ->
🥉
Kamada
A-Score
1-Year Total Return ->
4
Benchmark
A-Score
1-Year Total Return ->
5
Probi
A-Score
1-Year Total Return ->
6
